Menopausal hormone therapy treatment options and ovarian cancer risk: A Swedish prospective population‐based matched‐cohort study
Menopausal hormone replacement therapy (HRT) influences ovarian cancer. This survey of all Swedish women who received HRT between 2005-2012 looks at risk. HRT can be oestrogen only or combined oestrogen/progesterone, cutaneous administration is available. Some HRT is continuous some sequential.
The incidence of ovarian cancer was obtained from the Swedish Cancer Register. The therapy group was compared with a larger control group of women who did not receive HRT.
Current users of continuous combined HRT have a small increased risk being 1.4 times more likely to develop ovarian cancer. This risk is reduced by cutaneous therapy. Oestrogen only HRT is protective with a reduced incidence of ovarian cancer. There is no increased risk with sequential therapy. Once HRT is discontinued there is no increased risk.
No comments:
Post a Comment